Skip to main content

Advertisement

Table 2 Comparison of clinocopathological features by gene mutations status compared with all-wild type in patients with AGC patients

From: Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer

  All wild-type KRAS codon 12/13 PIK3CA exon 9/20 NRAS codon12/13
KRAS, BRAF, NRAS, PIK3CA Mutant type P-value Mutant type P–value Mutant type P-value
Number of patients 70 8   9   3  
Median age 64.0 54.5   58.0   56.0  
Gender (%)        
Male 49 (70.0) 7 (87.5) 0.429 8 (88.9) 0.432 2 (87.5) 1.000
Female 21 (30.0) 1 (12.5)   1 (11.1)   1 (12.5)  
ECOG PS (%)        
0 38 (54.3) 3 (37.5) 0.466 4 (44.4) 0.727 1 (33.3) 0.476
1 32 (45.7) 5 (62.5)   5 (55.6)   2 (66.7)  
Histological type (%)        
Intestinal type 20 (28.6) 6 (75.0) 0.014 4 (44.4) 0.443 0 (0.0) 0.556
Diffuse type 50 (71.4) 2 (25.0)   5 (55.6)   3 (100.0)  
No. of metastatic site (%)        
1 54 (77.1) 8 (100.0) 0.195 8 (88.9) 0.675 3 (100.0) 1.000
2 16 (22.9) 0 (0.0)   1 (11.1)   0 (0.0)  
Metastatic lesion (%)        
Lymph node 41 (58.6) 3 (37.5) 0.348 6 (66.7) 0.717 2 (66.7) 0.851
Liver 14 (20.0) 3 (37.5)   3 (33.3)   1 (33.3)  
Lung 2 (2.9) 1 (12.5)   0 (0.0)   0 (0.0)  
Peritoneal dissemination 18 (25.7) 1 (12.5)   1 (11.1)   0 (0.0)  
Other 3 (4.3) 0 (0.0)   0 (0.0)   0 (0.0)  
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status. We described the clinical data of 90 patients, and we excluded the patients whose tumor tissues had no gene mutations but at least one gene could not be evaluated.